One of Arcus’s key competitive advantages is a highly productive, industry-leading team of individuals that runs our world-class discovery engine and development organization. We believe that discovery is not a commodity, and we have invested in building exceptional small molecule, medicinal chemistry and antibody capabilities to optimize the combinability of molecules within our portfolio.
The development of our combination therapies in disease areas of high unmet need are guided by specific biologic mechanisms of cancer. Our deep understanding of disease biology enables us to quickly move from Phase 1 through commercialization.
Since its inception, Arcus has advanced its molecules from program initiation to investigational new drug (IND) filing in as short as 18 months, and accelerated platform and signal-seeking studies to move from proof–of-concept Phase 1 to randomized Phase 2 and registrational Phase 3 studies in just a few years.
Unity with the Cancer Community
We understand the urgent need of patients who are waiting for new treatment options. Collaboration is a core value at Arcus. Through thoughtful partnerships, Arcus has been able to facilitate participation in our clinical trials, with the goal of bringing new medicines to patients faster. It is through combining expertise with industry partners, patients and physicians that we aim to achieve our vision of Combining to Cure®.
World-class discovery engine
Leverage well-characterized biologic pathways to create molecules with outstanding clinical profiles and best-in-class potential
Combining to cure
Develop thoughtful, rational, biology-driven small molecule and monoclonal antibody combinations within our portfolio in the pursuit of cures
Fully integrated biopharmaceutical company
Assemble in-house capabilities from discovery through commercialization to be a global partner to the cancer community